Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach

[1]  Rohit Shukla,et al.  Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase , 2018, Journal of biomolecular structure & dynamics.

[2]  Dev Bukhsh Singh,et al.  Identification of potential inhibitors of Fasciola gigantica thioredoxin1: computational screening, molecular dynamics simulation, and binding free energy studies , 2018, Journal of biomolecular structure & dynamics.

[3]  Rohit Shukla,et al.  Distant Phe345 mutation compromises the stability and activity of Mycobacterium tuberculosis isocitrate lyase by modulating its structural flexibility , 2017, Scientific Reports.

[4]  V. Prajapati,et al.  Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation , 2017, Journal of biomolecular structure & dynamics.

[5]  S. Sundar,et al.  Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase , 2017, Journal of receptor and signal transduction research.

[6]  S. Sundar,et al.  Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation , 2017, Journal of biomolecular structure & dynamics.

[7]  V. Prajapati,et al.  Molecular Modeling and Virtual Screening Approach to Discover Potential Antileishmanial Inhibitors Against Ornithine Decarboxylase. , 2016, Combinatorial chemistry & high throughput screening.

[8]  K. Rock,et al.  Present Yourself! By MHC Class I and MHC Class II Molecules. , 2016, Trends in immunology.

[9]  S. Sundar,et al.  High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Shyamasree Ghosh,et al.  Biology of C Reactive Protein in Health and Disease , 2016, Springer India.

[11]  U. Holzgrabe,et al.  Cinnamic Acid Bornyl Ester Derivatives from Valeriana wallichii Exhibit Antileishmanial In Vivo Activity in Leishmania major-Infected BALB/c Mice , 2015, PloS one.

[12]  S. Sundar,et al.  Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach , 2015, Journal of biomolecular structure & dynamics.

[13]  T. Kaur,et al.  Immunogenicity and efficacy of recombinant 78 kDa antigen of Leishmania donovani formulated in various adjuvants against murine visceral leishmaniasis. , 2015, Asian Pacific journal of tropical medicine.

[14]  A. Fairlamb,et al.  Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar? , 2015, The Lancet.

[15]  Alan A. Dombkowski,et al.  Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins , 2013, BMC Bioinformatics.

[16]  M. Rai,et al.  In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. , 2013, The American journal of tropical medicine and hygiene.

[17]  S. Sundar,et al.  Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of Leishmania donovani. , 2013, Experimental parasitology.

[18]  S. Croft,et al.  Case study for a vaccine against leishmaniasis. , 2013, Vaccine.

[19]  B. Greenwood,et al.  Vaccines and global health , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  P. Kaye,et al.  Visceral leishmaniasis: immunology and prospects for a vaccine. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  S. Sundar,et al.  Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen. , 2010, Parasite immunology.

[22]  K. Kedzierska,et al.  Leishmaniasis: current treatment and prospects for new drugs and vaccines. , 2009, Current medicinal chemistry.

[23]  Wei Li,et al.  ElliPro: a new structure-based tool for the prediction of antibody epitopes , 2008, BMC Bioinformatics.

[24]  Vasant G Honavar,et al.  Predicting linear B‐cell epitopes using string kernels , 2008, Journal of molecular recognition : JMR.

[25]  J. Dujardin,et al.  Molecular Diagnosis of Leishmaniasis: Current Status and Future Applications , 2006, Journal of Clinical Microbiology.

[26]  L. Kedzierski,et al.  Leishmania vaccines: progress and problems , 2006, Parasitology.

[27]  Morten Nielsen,et al.  Improved method for predicting linear B-cell epitopes , 2006, Immunome research.

[28]  M. Barral-Netto,et al.  Leishmanial infection: analysis of its first steps. A review. , 2003, Memorias do Instituto Oswaldo Cruz.

[29]  J. Katiyar,et al.  Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. , 2001, Vaccine.

[30]  C. Bogdan,et al.  Leishmania-host-cell interaction: complexities and alternative views. , 2000, Parasitology today.

[31]  S. Makrides.  Strategies for achieving high-level expression of genes in Escherichia coli. , 1996, Microbiological reviews.

[32]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[33]  M. Horwitz,et al.  Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[35]  P. A. Peterson,et al.  Emerging principles for the recognition of peptide antigens by MHC class I molecules. , 1992, Science.

[36]  W. Taylor,et al.  A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.

[37]  Shyamasree Ghosh,et al.  Immune System: Freedom from the Burden of Diseases , 2016 .

[38]  Ronnie de Jonge,et al.  In silico identification and characterization of effector catalogs. , 2012, Methods in molecular biology.

[39]  C. Leclerc.  [New technologies for vaccine development]. , 2007, Medecine sciences : M/S.

[40]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[41]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[42]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.